European Journal of Cancer
Volume 46, Issue 1 , Pages 41-46 , January 2010

Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma

  • Katharina C. Kaehler

      Affiliations

    • Department of Dermatology, University of Kiel, Kiel, Germany
    • Corresponding Author InformationCorresponding author: Tel.: +49 4315971512; fax: +49 4315971853.
    • ,
  • Vernon K. Sondak

      Affiliations

    • Department of Cutaneous Oncology, Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    • Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA
    • Department of Surgery, University of South Florida, Tampa, FL, USA
    • ,
  • Dirk Schadendorf

      Affiliations

    • Department of Dermatology, University of Essen, Germany
    • ,
  • Axel Hauschild

      Affiliations

    • Department of Dermatology, University of Kiel, Kiel, Germany

Received 15 July 2009 ,Revised 23 September 2009

References 

  1. Caraglia M, Marra M, Pelaia G, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005;202:323–335
  2. Trepiakas R, Pedersen AE, Met O, et al. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine. 2009;27:2213–2219
  3. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000;68:556–567
  4. Baker DE. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord. 2003;3:93–109
  5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med. 2002;347:975–982
  6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–996
  7. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol. 2002;20:3841–3849
  8. Krepler C, Certa U, Wacheck V, et al. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol. 2004;123:664–669
  9. Grob JJ, Dreno B, De la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351:1905–1910
  10. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17
  11. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444–2458
  12. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370–2380
  13. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998;16:1425–1429
  14. Cameron DA, Cornbleet MC, MacKie RM, et al. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer. 2001;84:1146–1149
  15. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358:866–869
  16. Eggermont AM, Suciu S, MacKie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet. 2005;366:1189–1196
  17. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22:53–61
  18. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002;20:1818–1825
  19. Wheatley K. Interferon-alpha as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol. 2007;25(18 Suppl.):8526
  20. Garbe C, Eigentler T. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res. 2007;17:117–127
  21. Wheatley K, Ives N, Hancock B, Gore M. Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma. J Clin Oncol. 2002;20:4120–4121
  22. Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29:241–252
  23. Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008;372:117–126
  24. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009;27:2916–2923
  25. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748–759
  26. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res. 1993;3:291–299
  27. Dummer R, Garbe C, Thompson JA, et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol. 2006;24:1188–1194
  28. Spieth K, Kaufmann R, Dummer R, et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Annal Oncol. 2008;19:801–806[epub 2008 January 4]
  29. Hauschild A, Dummer R, Ugurel S, et al. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma. Cancer. 2008;113:1404–1411
  30. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25:3288–3295
  31. Ryan CW, Goldman BH, Lara PN, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II Study of the Southwest Oncology Group. J Clin Oncol. 2007;25:3296–3301

PII: S0959-8049(09)00729-1

doi: 10.1016/j.ejca.2009.10.004

European Journal of Cancer
Volume 46, Issue 1 , Pages 41-46 , January 2010

Article Tools

* Image Usage & Resolution